Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 3/20 | 0.47 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.46 |
| ▸ | MLNR | O43193 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858238 | 1.00 | KDM1A (0.48) | KDM1ATACR3FFAR2FASNMLNR | |
| SCHEMBL3857946 | 1.00 | KDM1A (0.48) | KDM1ATACR3FFAR2FASNMLNR | |
| Hydrochloric Acid SCHEMBL5758771 | 0.88 | MMP2 (0.52) | KDM1ATACR3FFAR2FASNCTSS | |
| Hydrochloric Acid SCHEMBL3859529 | 0.88 | MMP2 (0.52) | KDM1ATACR3FFAR2FASNCTSS | |
| SCHEMBL3862814 | 0.86 | CHRNB2 (0.53) | KDM1ATACR3FFAR2FASNCTSS | |
| Hydrochloric Acid SCHEMBL3856891 | 0.85 | CHRNB2 (0.51) | KDM1ATACR3FFAR2FASNCTSS | |
| SCHEMBL6787504 | 0.83 | LSS (0.51) | — | |
| Hydrochloric Acid SCHEMBL3857140 | 0.81 | CTSS (0.47) | KDM1ATACR3FFAR2FASNCTSS | |
| SCHEMBL13683836 | 0.80 | TACR3 (0.49) | KDM1ATACR3FFAR2FASNCTSS | |
| SCHEMBL13683678 | 0.80 | CTSS (0.46) | KDM1ATACR3FFAR2FASNCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592347-B2 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| EP-1615909-B1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LTD (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GLAXO GROUP LIMITED (GB) | 2007-03-08 | — | — | US | disclosed |
| CN-1809553-A | Piperazine derivatives and their use in the treatment of neurological and psychiatric disorders | GLAXO GROUP LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| EP-1615909-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004101546-A1 | PIPERAZINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES | GLAXO GROUP LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054917-A1 | Piperazine derivates and their use for the treatment of neurological and psychiatric diseases | GRIN2A, GRIK5, GRIN2C | KDM1A 1174/4885TACR3 1676/4885FFAR2 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.